A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease

PI Medical Director

Primary endpoint

Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score at Week 78

Population

Alzheimer's Disease; n=1643

Historical

Current

Future

3 noemes

Historical

1 noeme

Published findings from this trial. Vote whether the expert body still believes each noeme stands given current evidence.

The EMERGE (aducanumab) trial's stated primary conclusion — Aducanumab’s pivotal phase 3 showed mixed evidence for cognitive slowing in early Alzheimer disease. — replicates in independent cohorts.

neurology

Current

1 noeme

Noemes tracking active replication, subgroup analysis, or long-term follow-up. Vote on the likelihood the original effect holds.

Recent follow-up analyses of EMERGE (aducanumab) are confirming the original effect size in real-world data.

neurology

Future

1 noeme

Open forecast horizons tied to this trial. Vote your probability that each resolves TRUE by the declared horizon.

By 2028, aducanumab will have been withdrawn or deprioritized in favor of later anti-amyloid agents with cleaner efficacy signals.

neurology

Semantically related trials

Nearest trials by noeme-centroid cosine distance. Lower = closer.

NCT03887455

0.1131

· 3 claims

Lecanemab in Early Alzheimer’s Disease

NCT00829166

0.2197

· 3 claims

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

NCT03777059

0.2359

· 3 claims

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine (ADVANCE)

NCT01035255

0.2389

· 3 claims

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

NCT02386553

0.2431

· 3 claims

An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

NCT00354133

0.2453

· 3 claims

Neurostimulation for Parkinson's Disease with Early Motor Complications